Strong Angiomax showing bolsters Med Cos Q2 sales, income

| | Health Imaging | Diagnostic Imaging
finance, graph, business - 86.80 Kb
The Medicines Company has booked a solid 2012 second quarter, which ended June 30, partially augmented by sales of the direct thrombin inhibitor bivalirudin (Angiomax).

The net income for the second quarter of 2012 was $13.8 million, compared with net income of $11.4 million for the second quarter of 2011.

The company said that its net revenue increased by 13.5 percent to $135.7 million for the second quarter of 2012 from $119.6 million in the second quarter of 2011.

Specifically, Angiomax U.S. sales increased by 8.2 percent to $121.2 million in the second quarter of 2012 compared with $112 million in the second quarter of 2011. The Angiomax/Angiox international net revenue in the second quarter of 2012 increased by 63.6 percent to $11.9 million compared with $7.3 million in the second quarter of 2011.

"For the first half of 2012, revenue growth has been robust with Europe a particular bright spot -- while we have kept worldwide SG&A [selling, general and administrative] costs stable,” said Glenn Sblendorio, president and chief financial officer at Medicines Company. “Our R&D projects are moving forward aggressively to drive toward answers on our critical Phase 3 trials of oritavancin and cangrelor."

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.